Verici DX: Conference attendance at Mello2026 Investor event

Verici Dx plc

(“Verici Dx” or the “Company”)

Conference attendance at Mello2026 Investor event

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Verici Dx will be presenting and exhibiting at the Mello2026 investor event on Tuesday 17 November, which will be held at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.

Sara Barrington, CEO, will be presenting at 12:25pm and 16:45pm on the day, providing an overview of the Company and strategy, as well as discussing the recent successful fundraise, which management anticipates will provide sufficient runway to achieve cash-flow breakeven by the end of 2027. No new information will be disclosed at the event, and a PDF of the presentation will be made available on the Company’s website at https://vericidx.com/investors/.

For further information and tickets for the Mello2026 conference, please visit the event website at https://www.melloevents.com/mellolondon2026.

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.

Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.

The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.